![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, June 23, 2021 1:37:52 PM
(( IMO Anavex could not have found a better buyer of it's stock. This will be a long and strong hold. Note the education level and business experiences, mostly Doctors and PhDs. The fact that with their elite background that they invested in Anavex is a positive validation for Anavex. ))
Deep Track Capital which Deep Track Capital is a Greenwich, Connecticut-based investment firm focused exclusively on the life sciences industry. We develop long term partnerships with management teams of leading innovative public and pre-IPO biotechnology companies. In addition to capital, we seek to invest our time and expertise, while leveraging our network for the benefit of our partners. We aim to lead transactions while building large syndicates, and also to invest in rounds led by other qualified investors.
Who we are:
David Kroin Founder and Chief Investment Officer; David earned a Bachelor of Science in Actuarial Mathematics from the University of Michigan and serves on the leadership council of the University’s Life Sciences Institute. He has served on numerous boards of public and private health care companies (including, CellCarta, Cytovance, CorEvitas, Mediatech, ProPT, Biodel, APT, Gentium and US Bioservices
Rael Mazansky, MD/MBA Managing Director; his Medical Doctorate from the Columbia University College of Physicians and Surgeons and a Master’s Degree in Business Administration from the Columbia University Graduate School of Business.
Steven Breazzano, Ph.D. Principal; Steve earned a Master of Science in Chemistry and a Bachelor of Arts in both Chemistry and Biochemistry from Brandeis University and his Ph.D. in Chemistry from The Scripps Institute
Rebecca Luse Principal; Rebecca earned a Bachelor of Science in Biochemistry and Mathematics from Indiana University.
Gerard Smith, MD/MBA Principal; Gerard earned both his Medical Doctorate and Master’s in Business Administration from University of Miami and a Bachelor of Science in Psychology from Virginia Commonwealth University. Following medical school, Gerard was a resident physician in Anesthesiology at the VCU Health System prior to joining the equity research department at Leerink Partners (now SVB Leerink), where he became a Vice President covering biotechnology companies for two years.
Aaron Hakim, MD Exclusive Consultant; Aaron Hakim, MD is a resident physician in internal medicine at Beth Israel Deaconess Medical Center and a clinical fellow at Harvard Medical School. Previously, Aaron was a Vice President at Great Point Partners, a biotechnology-focused investment fund where he worked with David for seven years. His research has appeared in peer reviewed journals including the Journal of Hepatology, the Journal of the American Medical Association, and the Journal of Biological Chemistry. Aaron earned his medical degree with honors at Yale School of Medicine and graduated summa cum laude from Yale University with an M.S. in Molecular Biology and a B.S. in Economics and Molecular Biology.
Rod Lim, Ph.D. Associate; Prior to joining Deep Track, Rod was a Vice President in the healthcare investment banking group at Jeffries Financial Group, where focused exclusively on biopharmaceutical companies for approximately two years and prior to that, worked for a year and a half in the business development team at Samsung Bioepis, evaluating venture investments for Samsung’s biotech fund, as well as in-licensing opportunities. Rod has a Ph. D. and an M.S. in Neurobiology/CNS from the California Institute of Technology, and a B.S. in Molecular Biology and a M.S in Cancer Biology from the University of California, San Diego.
Chris Margono, MD Associate: Chris earned his Medical Doctorate from the University of California at San Francisco (UCSF) where was awarded the school of medicine dean’s research prize, and a Bachelor of Science in Chemistry from University of California at Riverside. Following his MD., Chris spent almost two years as a consultant at Simon-Kucher & Partners focusing on the health care and life sciences sector. Previously he was a summer intern at Aquillo Capital Management, a biotechnology focused hedge fund.
Janet Okogbaa, MD Associate; Janet earned her Medical Doctorate with a scholarly concentration in bioengineering and healthcare investing from Stanford University, and a Bachelor of Arts in Human Biology from Stanford University.
Timothy Zhou, Associate: Prior to joining Deep Track Capital, Tim was an Associate at Novo Ventures focused on public and crossover investments in the biotech and medical technology sectors. Previously, he worked at Bank of America Merrill Lynch in the healthcare investment banking group, where he advised public and private biotech and pharmaceutical companies on strategic and financing matters. Tim earned a Bachelor of Science in Bioengineering from the University of Pennsylvania and a Bachelor of Science in Economics (Concentration in Finance) from the Wharton School.
Janet Okogbaa, MD, Associate; Janet earned her Medical Doctorate with a scholarly concentration in bioengineering and healthcare investing from Stanford University, and a Bachelor of Arts in Human Biology from Stanford University. Following her MD., Janet spent two years as an investment banking associate at Lazard Freres, focusing on the health care and life sciences sector, and the past year and one half as a buyside research analyst at Millennium Management focusing on biotechnology
Timothy Zhou, Associate; Prior to joining Deep Track Capital, Tim was an Associate at Novo Ventures focused on public and crossover investments in the biotech and medical technology sectors. Previously, he worked at Bank of America Merrill Lynch in the healthcare investment banking group, where he advised public and private biotech and pharmaceutical companies on strategic and financing matters. Tim earned a Bachelor of Science in Bioengineering from the University of Pennsylvania and a Bachelor of Science in Economics (Concentration in Finance) from the Wharton School.
Plus 4 more.
Link: https://www.deeptrackcapital.com/team
Recent AVXL News
- Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference • GlobeNewswire Inc. • 06/20/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 11:30:10 AM
- Anavex Life Sciences Announces Expansion of Leadership Team • GlobeNewswire Inc. • 05/22/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 10:01:00 AM
- Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ • GlobeNewswire Inc. • 05/14/2024 11:30:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) Urged to Join Class Action - Contact The Gross Law Firm to Learn More • PR Newswire (US) • 05/10/2024 09:45:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:35:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 12:00:30 PM
- Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/09/2024 11:30:00 AM
- The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Anavex Life Sciences Corporation(AVXL) Shareholders • PR Newswire (US) • 05/07/2024 09:45:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/06/2024 10:03:33 AM
- Anavex Life Sciences Corporation Sued for Securities Law Violations - Contact The Gross Law Firm Before May 13, 2024 to Discuss Your Rights - AVXL • PR Newswire (US) • 05/03/2024 09:45:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024 • GlobeNewswire Inc. • 05/02/2024 11:30:00 AM
- May 13, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against AVXL • PR Newswire (US) • 04/26/2024 09:45:00 AM
- Contact The Gross Law Firm by May 13, 2024 Deadline to Join Class Action Against Anavex Life Sciences Corporation(AVXL) • PR Newswire (US) • 04/19/2024 09:45:00 AM
- The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 13, 2024 in Anavex Life Sciences Lawsuit - AVXL • PR Newswire (US) • 04/16/2024 09:45:00 AM
- Class Action Filed Against Anavex Life Sciences Corporation (AVXL) - May 13, 2024 Deadline to Join - Contact The Gross Law Firm • PR Newswire (US) • 04/12/2024 09:45:00 AM
- Anavex Life Sciences to Present at the Noble Capital Markets Virtual Healthcare Equity Conference • GlobeNewswire Inc. • 04/11/2024 11:30:00 AM
- Class Action Filed Against Anavex Life Sciences Corporation (AVXL) - May 13, 2024 Deadline to Join - Contact The Gross Law Firm • PR Newswire (US) • 04/09/2024 09:45:00 AM
- Anavex Life Sciences Corporation Class Action: The Gross Law Firm Reminds Anavex Life Sciences Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 13, 2024 - AVXL • PR Newswire (US) • 04/05/2024 09:45:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) should contact The Gross Law Firm about pending Class Action - AVXL • PR Newswire (US) • 04/02/2024 09:45:00 AM
- Lost Money on Anavex Life Sciences Corporation(AVXL)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm • PR Newswire (US) • 03/29/2024 09:45:00 AM
- Investors who lost money on Anavex Life Sciences Corporation(AVXL) should contact The Gross Law Firm about pending Class Action - AVXL • PR Newswire (US) • 03/26/2024 09:45:00 AM
- Anavex Life Sciences to Present at the 23rd Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 03/25/2024 11:30:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM